Iterion Therapeutics, a clinical-stage biotechnology company, has secured $7,100,000 in investment capital from investors. This funding round marks a significant step for the company as it advances its novel small-molecule therapies for aggressive cancers.
The company focuses on developing treatments that target the Wnt/β-catenin signaling pathway, an oncogenic driver that has historically been challenging to address. Iterion's lead asset, Tegavivint, is a first-in-class inhibitor of TBL1 (Transducin β-like protein 1). Tegavivint functions by promoting the degradation of nuclear β-catenin and inhibiting Wnt-activated oncogenic transcription, a mechanism designed to offer a differentiated safety and efficacy profile compared to previous approaches.
The newly raised capital will be instrumental in supporting the continued development of Tegavivint. The company plans to use these funds to advance its ongoing Phase 2 clinical program in hepatocellular carcinoma (HCC). Furthermore, the investment will facilitate the exploration of expansion opportunities for Tegavivint into other Wnt-driven cancers where there is a high unmet medical need. Clinical studies to date have shown Tegavivint demonstrating encouraging anti-tumor activity and durable disease control, particularly in patients with HCC and desmoid tumors.
With this new funding, Iterion Therapeutics is poised to further its mission of unlocking the therapeutic potential of Wnt/β-catenin inhibition. The company aims to deliver first-in-class targeted therapies, supporting its growth plans and ultimately striving to address critical needs for patients battling aggressive cancers.
.png&w=3840&q=75)
